Valuation: Bellicum Pharmaceuticals, Inc.

Market Cap 1.76M 1.58M 1.45M 1.32M 2.49M 166M 2.57M 17.44M 6.95M 88.52M 6.62M 6.48M 279M P/E 2021
-1.77x
P/E 2022 -0.89x
Enterprise Value -20.07M -18M -16.45M -15.02M -28.3M -1.89B -29.19M -198M -79.08M -1.01B -75.34M -73.73M -3.18B EV / Sales 2021
-5.43x
EV / Sales 2022 -10.4x
Free-Float
98.45%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 66 22/02/2024
Chief Executive Officer 57 30/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-6.68%-18.17% - - 822K
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average -0.39%+3.25%+56.16%+144.47% 45.09B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.96%

Financials

2021 2022
Net sales 6.2M 5.56M 5.08M 4.64M 8.74M 583M 9.02M 61.26M 24.43M 311M 23.27M 22.77M 982M 1.5M 1.35M 1.23M 1.12M 2.11M 141M 2.18M 14.82M 5.91M 75.24M 5.63M 5.51M 238M
Net income -9.7M -8.7M -7.96M -7.26M -13.68M -912M -14.11M -95.89M -38.23M -487M -36.43M -35.65M -1.54B -24.97M -22.4M -20.47M -18.69M -35.21M -2.35B -36.32M -247M -98.39M -1.25B -93.74M -91.73M -3.95B
Net Debt -46.16M -41.4M -37.83M -34.54M -65.07M -4.34B -67.12M -456M -182M -2.32B -173M -170M -7.31B -21.84M -19.59M -17.9M -16.34M -30.78M -2.05B -31.76M -216M -86.03M -1.1B -81.97M -80.21M -3.46B
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13